Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate
2. Bms-927711
3. Nurtec Odt
4. Rimegepant
1. Nurtec Odt
2. Rimegepant Sulfate [usan]
3. 1374024-48-2
4. 1383nm3q0h
5. Rimegepant Sulfate (usan)
6. 1-piperidinecarboxylic Acid, 4-(2,3-dihydro-2-oxo-1h-imidazo(4,5-b)pyridin-1-yl)-, (5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl Ester, Sulfate, Hydrate (2:1:3)
7. Di((5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate), Monosulfate, Trihydrate
8. Unii-1383nm3q0h
9. Nurtec Odt (tn)
10. Rimegepant Sulfate Dihydrate
11. Chembl2364629
12. Dtxsid60160174
13. Rimegepant Sulfate [who-dd]
14. Rimegepant Sulfate [orange Book]
15. Rimegepant Hemisulfate Sesquihydrate
16. D10663
17. Rimegepant Hemisulfate Sesquihydrate [mi]
18. Q27251488
| Molecular Weight | 1221.2 g/mol |
|---|---|
| Molecular Formula | C56H64F4N12O13S |
| Hydrogen Bond Donor Count | 9 |
| Hydrogen Bond Acceptor Count | 23 |
| Rotatable Bond Count | 8 |
| Exact Mass | 1220.43726396 g/mol |
| Monoisotopic Mass | 1220.43726396 g/mol |
| Topological Polar Surface Area | 313 Ų |
| Heavy Atom Count | 86 |
| Formal Charge | 0 |
| Complexity | 973 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 6 |
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-14
Pay. Date : 2023-09-26
DMF Number : 37797
Submission : 2022-12-23
Status : Active
Type : II
NDC Package Code : 81912-0002
Start Marketing Date : 2023-09-22
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43413
Submission : 2025-12-29
Status : Active
Type : II
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-09-25
Pay. Date : 2023-08-24
DMF Number : 38655
Submission : 2023-08-14
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-13
Pay. Date : 2023-08-14
DMF Number : 38715
Submission : 2023-09-28
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41826
Submission : 2025-06-25
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41624
Submission : 2025-03-28
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-14
Pay. Date : 2023-09-26
DMF Number : 37797
Submission : 2022-12-23
Status : Active
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43413
Submission : 2025-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41624
Submission : 2025-03-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-11-13
Pay. Date : 2023-09-15
DMF Number : 38810
Submission : 2023-09-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-09-25
Pay. Date : 2023-08-24
DMF Number : 38655
Submission : 2023-08-14
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-11-21
Pay. Date : 2023-09-27
DMF Number : 38834
Submission : 2023-09-29
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41826
Submission : 2025-06-25
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-11-13
Pay. Date : 2023-08-14
DMF Number : 38715
Submission : 2023-09-28
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2025-12-24
Valid Till : 2028-09-15
Written Confirmation Number : WC-0536
Address of the Firm : Unit-I, No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial area, Phase 1,...

Date of Issue : 2025-07-24
Valid Till : 2028-06-05
Written Confirmation Number : WC-0523
Address of the Firm : Unit-ll, No. 276-P, & 277-P, Sy No. 20, Bannikuppe Road, Harohalli Industrial Ar...

Date of Issue : 2025-09-24
Valid Till : 2028-08-08
Written Confirmation Number : WC-0383
Address of the Firm : Unit-ll, Sy No * Parts of 454,455,457,458 & 459 Chandampet-Village, Shankarampet...

Rimegepant Sulphate (BHV-)/FCI IH
Date of Issue : 2025-12-10
Valid Till : 2028-07-02
Written Confirmation Number : WC-0123
Address of the Firm : Sy. Nos. 7-70, 70/1 & 70/2, Digwal Village, Kohir Mandal, Sangareddy District, T...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Pfizer Korea
Registration Date : 2025-03-24
Registration Number : Su87-41-ND
Manufacturer Name : Anthem Biosciences Limited, ...
Manufacturer Address : No. 49, F1 & F2 Canara Bank Road, BommasandraIndustrial Area, Phase I, Bommasandra, B...

Registrant Name : Pfizer Korea
Registration Date : 2025-03-24
Registration Number : Su87-42-ND
Manufacturer Name : Anthem Biosciences Limited, ...
Manufacturer Address : Plot No. 276-P & 277-P, SY. No. 20, Bannikuppe Road, Harohalli Industrial Area, Phase...

Registrant Name : Pfizer Korea
Registration Date : 2025-03-24
Registration Number : Su87-43-ND
Manufacturer Name : Escientia Advanced Sciences ...
Manufacturer Address : Plot No.11, 11A, 12 and 12A, APSEZ, Atchutapuram, Anakapalli District - 531011, Andhr...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Since 1962, MOEHS has produced high-quality Active Pharmaceutical Ingredients (APIs) for the global market. With decades of technical expertise, Moehs Group delivers pharmaceutical...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-growth therapeutic ar...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
About the Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With facilities conforming ...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
About the Company : Siegfried is a global Contract Development and Manufacturing Organization providing integrated services for pharmaceutical ingredients & finished dosage forms. With 13 production s...
About the Company : Bajaj Healthcare Ltd. is a company established in 1993, services various Pharmaceuticals, Nutraceutical and Food industries globally with a spirit of scrupulousness. Bajaj Healt...

About the Company : Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu Province, China. The company was fou...

About the Company : Hebi Xinhe Pharmaceutical Co., Ltd. is a subsidiary of Tianjin Zhennuo Pharmaceutical Group Co., Ltd., with a registered capital of CNY 100 million. Located in Jijiashan Industrial...

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Rimegepant Sulfate is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 24, 2025

Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rimegepant Sulfate is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rimegepant Sulfate, a miscellaneous product targeting the calcitonin gene-related peptide type 1 receptor, shows promise in treating migraines.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Rimegepant ODT
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfizer Launches Rimegepant Oral Medication for Migraine in India
Details : Rimegepant Sulfate, a miscellaneous product targeting the calcitonin gene-related peptide type 1 receptor, shows promise in treating migraines.
Product Name : Rimegepant ODT
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2025

Details:
Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Rimegepant Sulfate,Zavegepant HCl
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2025

Lead Product(s) : Rimegepant Sulfate,Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Acute Migraine Treatment in the ED with Gepants
Details : Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
Details : Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Rimegepant and Placebo for Pain in IBS
Details : Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vydura (also known as Rimegepant) is an oral lyophilisate and is the first calcitonin gene-related peptide (CGRP) receptor antagonist migraine therapy to be accepted by the SMC.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Vydura
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Biohaven Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biohaven Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
First-In-Class Migraine Treatment Vydura Approved for NHS Scotland
Details : Vydura (also known as Rimegepant) is an oral lyophilisate and is the first calcitonin gene-related peptide (CGRP) receptor antagonist migraine therapy to be accepted by the SMC.
Product Name : Vydura
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 10, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 12, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 12, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists including NURTEC® ODT (rimegepant), to address needs of millions of migraine patients worldwide.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Nurtec ODT
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: $11,600.0 million Upfront Cash: $11,600.0 million
Deal Type: Acquisition October 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $11,600.0 million
Deal Type : Acquisition
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Details : The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide (CGRP) receptor antagonists including NURTEC® ODT (rimegepant), to address needs of millions of migraine patients worldwide.
Product Name : Nurtec ODT
Product Type : Miscellaneous
Upfront Cash : $11,600.0 million
October 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Rimegepant Sulfate,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rimegepant Sulfate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rimegepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results](5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-...
CAS Number : 1373116-07-4
End Use API : Rimegepant Sulfate
About The Company : Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical int...
1,3-Dihydro-1-[1-(1H-imidazol-1-ylcarbonyl)-4-pipe...
CAS Number : 1373116-06-3
End Use API : Rimegepant Sulfate
About The Company : Saiming Pharmaceutical is a technology-driven company with 12+ years of experience. Our business involves the R&D, production, and trading of pharmaceutical int...
1-(PIPERIDIN-4-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-B] ...
CAS Number : 781649-84-1
End Use API : Rimegepant Sulfate
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

CAS Number : 3612-20-2
End Use API : Rimegepant Sulfate
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

CAS Number : 5382-16-1
End Use API : Rimegepant Sulfate
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

ETHYL 4-OXOPIPERIDINE-1-CARBOXYLATE / N-CARBETHOX...
CAS Number : 29976-53-2
End Use API : Rimegepant Sulfate
About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

Dimethyl-5,9-dihydroxy-7H-cyclohepta [?] pyridine-...
CAS Number : 39713-36-5
End Use API : Rimegepant Sulfate
About The Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expert...

7,8-dihydro-5H-cyclohepta[b]pyridine-5,9(6H)-dione
CAS Number : 39713-40-1
End Use API : Rimegepant Sulfate
About The Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expert...

1,3-Dihydro-1-(4-piperidinyl)-2H-imidazo[4,5-b]pyr...
CAS Number : 781649-84-1
End Use API : Rimegepant Sulfate
About The Company : Guangzhou AANpharm Technology is a science-driven producer of key starting materials, pharmaceutical intermediates and specialty chemicals for CDMOs, API manufa...

5H-Cyclohepta[b]pyridine-7,8-dihydro-5,9(6H)-dione
CAS Number : 39713-40-1
End Use API : Rimegepant Sulfate
About The Company : Guangzhou AANpharm Technology is a science-driven producer of key starting materials, pharmaceutical intermediates and specialty chemicals for CDMOs, API manufa...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 213
2021 Revenue in Millions : 0
Growth (%) : 100

Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 928
2022 Revenue in Millions : 213
Growth (%) : 336

Main Therapeutic Indication : Neurology
Currency : USD
2024 Revenue in Millions : 1,263
2023 Revenue in Millions : 928
Growth (%) : 36

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
06 May 2026
Reply
02 Dec 2025
Reply
03 Sep 2025
Reply
17 Jul 2025
Reply
17 Feb 2025
Reply
25 Jan 2025
Reply
29 Aug 2024
Reply
07 Aug 2024
Reply
07 Jul 2022
Reply
04 May 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
25
PharmaCompass offers a list of Rimegepant Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Rimegepant Sulfate manufacturer or Rimegepant Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rimegepant Sulfate manufacturer or Rimegepant Sulfate supplier.
A Rimegepant Sulfate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rimegepant Sulfate, including repackagers and relabelers. The FDA regulates Rimegepant Sulfate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rimegepant Sulfate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rimegepant Sulfate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Rimegepant Sulfate supplier is an individual or a company that provides Rimegepant Sulfate active pharmaceutical ingredient (API) or Rimegepant Sulfate finished formulations upon request. The Rimegepant Sulfate suppliers may include Rimegepant Sulfate API manufacturers, exporters, distributors and traders.
click here to find a list of Rimegepant Sulfate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Rimegepant Sulfate DMF (Drug Master File) is a document detailing the whole manufacturing process of Rimegepant Sulfate active pharmaceutical ingredient (API) in detail. Different forms of Rimegepant Sulfate DMFs exist exist since differing nations have different regulations, such as Rimegepant Sulfate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rimegepant Sulfate DMF submitted to regulatory agencies in the US is known as a USDMF. Rimegepant Sulfate USDMF includes data on Rimegepant Sulfate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rimegepant Sulfate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rimegepant Sulfate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rimegepant Sulfate Drug Master File in Korea (Rimegepant Sulfate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rimegepant Sulfate. The MFDS reviews the Rimegepant Sulfate KDMF as part of the drug registration process and uses the information provided in the Rimegepant Sulfate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rimegepant Sulfate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rimegepant Sulfate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rimegepant Sulfate suppliers with KDMF on PharmaCompass.
A Rimegepant Sulfate written confirmation (Rimegepant Sulfate WC) is an official document issued by a regulatory agency to a Rimegepant Sulfate manufacturer, verifying that the manufacturing facility of a Rimegepant Sulfate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rimegepant Sulfate APIs or Rimegepant Sulfate finished pharmaceutical products to another nation, regulatory agencies frequently require a Rimegepant Sulfate WC (written confirmation) as part of the regulatory process.
click here to find a list of Rimegepant Sulfate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rimegepant Sulfate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rimegepant Sulfate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rimegepant Sulfate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rimegepant Sulfate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rimegepant Sulfate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rimegepant Sulfate suppliers with NDC on PharmaCompass.
Rimegepant Sulfate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rimegepant Sulfate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Rimegepant Sulfate GMP manufacturer or Rimegepant Sulfate GMP API supplier for your needs.
A Rimegepant Sulfate CoA (Certificate of Analysis) is a formal document that attests to Rimegepant Sulfate's compliance with Rimegepant Sulfate specifications and serves as a tool for batch-level quality control.
Rimegepant Sulfate CoA mostly includes findings from lab analyses of a specific batch. For each Rimegepant Sulfate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rimegepant Sulfate may be tested according to a variety of international standards, such as European Pharmacopoeia (Rimegepant Sulfate EP), Rimegepant Sulfate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rimegepant Sulfate USP).